Search Results - "Solal‐Celigny, P."

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte by FEUGIER, P, VAN HOOF, A, GAULARD, P, SALLES, G, BOSLY, A, GISSELBRECHT, C, REYES, F, COIFFIER, B, SEBBAN, C, SOLAL-CELIGNY, P, BOUABDALLAH, R, FERME, C, CHRISTIAN, B, LEPAGE, E, TILLY, H, MORSCHHAUSER, F

“…To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine,…”
Get full text

Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma by Rohatiner, A Z S, Gregory, W M, Peterson, B, Borden, E, Solal-Celigny, P, Hagenbeek, A, Fisher, R I, Unterhalt, M, Arranz, R, Chisesi, T, Aviles, A, Lister, T A

“…To determine whether interferon (IFN) -alpha2, when given with or following chemotherapy, influences response rate, remission duration, and survival in newly…”
Get full text

Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review by Damaj, G., Verkarre, V., Delmer, A., Solal-Celigny, P., Yakoub-Agha, I., Cellier, C., Maurschhauser, F., Bouabdallah, R., Leblond, V., Lefrère, F., Bouscary, D., Audouin, J., Coiffier, B., Varet, B., Molina, T., Brousse, N., Hermine, O.

“…Background: To describe better the clinical, biological, endoscopic and pathological presentations, as well as the outcome, of primary follicular lymphoma (FL)…”
Get full text

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial by Rossille, D, Gressier, M, Damotte, D, Maucort-Boulch, D, Pangault, C, Semana, G, Le Gouill, S, Haioun, C, Tarte, K, Lamy, T, Milpied, N, Fest, T

“…The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient…”
Get full text

Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma by Dumontet, C., Morschhauser, F., Solal‐Celigny, P., Bouafia, F., Bourgeois, Emmanuelle, Thieblemont, C., Leleu, Xavier, Hequet, O., Salles, G., Coiffier, B.

“…A multicentre phase II trial was conducted to evaluate the efficacy and toxicity of gemcitabine in patients with refractory or relapsed indolent non‐Hodgkin's…”
Get full text

Follicular Lymphoma International Prognostic Index by Solal-Céligny, Philippe, Roy, Pascal, Colombat, Philippe, White, Josephine, Armitage, Jim O., Arranz-Saez, Reyes, Au, Wing Y., Bellei, Monica, Brice, Pauline, Caballero, Dolores, Coiffier, Bertrand, Conde-Garcia, Eulogio, Doyen, Chantal, Federico, Massimo, Fisher, Richard I., Garcia-Conde, Javier F., Guglielmi, Cesare, Hagenbeek, Anton, Haïoun, Corinne, LeBlanc, Michael, Lister, Andrew T., Lopez-Guillermo, Armando, McLaughlin, Peter, Milpied, Noël, Morel, Pierre, Mounier, Nicolas, Proctor, Stephen J., Rohatiner, Ama, Smith, Paul, Soubeyran, Pierre, Tilly, Hervé, Vitolo, Umberto, Zinzani, Pier-Luigi, Zucca, Emanuele, Montserrat, Emili

“…The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help in evaluating…”
Get full text

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up by Colombat, P., Brousse, N., Salles, G., Morschhauser, F., Brice, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Tilly, H., Thieblemont, C., Bergougnoux, L., Lazreg, F., Solal-Celigny, P.

“…The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). Of…”
Get full text

Radiation myositis: The possible role of gemcitabine by Ganem, G., Solal-Celigny, P., Joffroy, A., Tassy, D., Delpon, A., Dupuis, O.

Get full text

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor by Gouilleux‐Gruart, V., Chapel, H., Chevret, S., Lucas, M., Malphettes, M., Fieschi, C., Patel, S., Boutboul, D., Marson, M.‐N., Gérard, L., Lee, M., Watier, H., Oksenhendler, E., Galicier, L., Fermand, J.P., Viallard, J.F., Jaccard, A., Hoarau, C., Lebranchu, Y., Bérezné, A., Mouthon, L., Karmochkine, M., Georgin‐Lavialle, S., Schleinitz, N., Durieu, I., Nove‐Josserand, R., Chanet, V., Le‐Moing, V., Just, N., Salanoubat, C., Jaussaud, R., Suarez, F., Hermine, O., Solal‐Celigny, P., Hachulla, E., Sanhes, L., Gardembas, M., Pellier, I., Tisserant, P., Pavic, M., Bonnotte, B., Haroche, J., Amoura, Z., Alric, L., Thiercelin, M.F., Tetu, L., Adoue, D., Bordigoni, P., Perpoint, T., Sève, P., Rohrlich, P., Pasquali, J.L., Soulas, P., Couderc, L.J., Catherinot, E., Giraud, P., Baruchel, A., Deleveau, I., Chaix, F., Donadieu, J., Tron, F., Larroche, C., Blanc, AP, Masseau, A., Hamidou, M., Kanny, G., Morisset, M., Millot, F., Fain, O., Borie, R., Perlat, A., Martinez, V., Bienvenu, B., Debré, P., Mouillot, G., Théodorou, I., Rabian, C., Carmagnat, M., Vince, N., Bono, C.

“…Summary Treatment of common variable immunodeficiency disorders (CVID) is based on replacement therapy using intravenous (i.v.) or subcutaneous (s.c.)…”
Get full text

Phase II study of gemcitabine–dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma by Morschhauser, F., Depil, S., Jourdan, E., Wetterwald, M., Bouabdallah, R., Marit, G., Solal-Céligny, P., Sebban, C., Coiffier, B., Chouaki, N., Bauters, F., Dumontet, C.

“…Single-agent gemcitabine has shown encouraging results in patients with mantle cell lymphoma (MCL). This phase II study further explored the potential of a…”
Get full text

Follicular non-Hodgkin's lymphoma by Hayashi, D, Lee, J.C, Devenney-Cakir, B, Zaim, S, Ounadjela, S, Solal-Céligny, P, Juweid, M, Guermazi, A

“…Follicular non-Hodgkin's lymphoma (NHL) is a unique subtype of NHL, which is indolent, incurable with a high prevalence of residual mass after treatment, and…”
Get full text

Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment by Cartron, G., Ohresser, M., Salles, G., Solal-Céligny, P., Colombat, P., Watier, H.

“…Neutrophils could play an important role in in vivo rituximab anti-lymphoma activity. FcγRIIIb is expressed only by neutrophils and FcγRIIIb-neutrophil antigen…”
Get full text

18F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group by Cahu, X., Bodet-Milin, C., Brissot, E., Maisonneuve, H., Houot, R., Morineau, N., Solal-Celigny, P., Godmer, P., Gastinne, T., Moreau, P., Moreau, A., Lamy, T., Kraber-Bodere, F., Le Gouill, S.

“…In non-cutaneous T-cell/natural killer (T/NK) lymphomas, the prognostic value of 18F-fluorodeoxyglucose–positron emission tomography (FDG–PET) during or after…”
Get full text

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial by Solal-Céligny, P, Lepage, E, Brousse, N, Tendler, C L, Brice, P, Haïoun, C, Gabarre, J, Pignon, B, Tertian, G, Bouabdallah, R, Rossi, J F, Doyen, C, Coiffier, B

“…To compare progression-free survival (PFS), overall survival (OS), and toxicity of a doxorubicin-containing regimen administered alone or in combination with…”
Get more information

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody) : Analysis of factors associated with response by FORAN, J. M, CUNNINGHAM, D, LISTER, T. A, COIFFIER, B, SOLAL-CELIGNY, P, REYES, F, GHIELMINI, M, JOHNSON, P. W. M, GISSELBRECHT, C, BRADBURN, M, MATTHEWS, J

“…A retrospective analysis was performed to delineate the factors associated with response, and to determine the duration of response, in 87 patients with…”
Get full text

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol by Brice, P., Simon, D., Bouabdallah, R., Bélanger, C., Haïoun, C., Thieblemont, C., Tilly, H., Harousseau, J. L., Doyen, C., Martin, C., Brousse, N., Solal-Céligny, Ph

“…Background: Among the 566 patients with follicular lymphomas (FL) included in the GELF 86 prospective trials from October 1986 to September 1995, 372 with…”
Get full text

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte by Solal-Céligny, P, Brice, P, Brousse, N, Caspard, H, Bastion, Y, Haïoun, C, Bosly, A, Tilly, H, Bordessoule, D, Sebban, C, Harousseau, J L, Morel, P, Dupas, B, Plassart, F, Vasile, N, Fort, N, Leporrier, M

“…Fludarabine monophosphate (FAMP) is a major drug in the treatment of chronic lymphocytic leukemia and showed efficacy in selected groups of patients with…”
Get more information

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial by Depierre, A, Chastang, C, Quoix, E, Lebeau, B, Blanchon, F, Paillot, N, Lemarie, E, Milleron, B, Moro, D, Clavier, J

“…The purpose of the study was to assess the possible benefit of the combination vinorelbine (NVB)-cisplatin (DDP) in comparison with NVB alone in advanced…”
Get more information

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study by Bourgeois, H., Grudé, F., Solal-Céligny, P., Dupuis, O., Voog, E., Ganem, G., Denis, F., Zinger, M., Juhel-Voog, L., Lafond, C., Maillart, P., Capitain, O., Delva, R., Soulié, P., Abadie-Lacourtoisie, S., Guérin-Meyer, V., Morin-Meschin, M.E., Commer, J.M., Gangler, A., d’Aillières, B., Zannetti, A., Bourbouloux, E., Berton-Rigault, D., Lebouvier-Sadot, S., Kaassis, M., Baudon, J., Lam, Y.H., Bizieux, A., Marcq, M., Edeline, J., Le Du, F., Lefeuvre, C., Deguiral, P., Delecroix, V., Blot, E., Egreteau, J., Goudier, M.J., Lamy, R., Ferec, M., Artignan, X., Corbinais, S., Morel, H., Hardy-Bessard, A.C., Alleaume, C., Naudeix, E., Cojocarasu, O., Metges, J.P., Riché, C., Gamelin, E., Déniel-Lagadec, D., Marhuenda, F., Ingrand, P., Douillard, J.Y.

“…In 2008, a study of the characteristics of hospitalised patients led to the development of a prognostic tool that distinguished three populations with…”
Get full text

Chronic Myelomonocytic Leukemia According to FAB Classification: Analysis of 35 Cases by Solal-Celigny, Philippe, Desaint, Benoit, Herrera, Alain, Chastang, Claude, Amar, Michèle, Vroclans, Milia, Brousse, Nicole, Mancilla, Françoise, Renoux, Michel, Bernard, Jean-François, Boivin, Pierre

“…Thirty-five patients who fulfilled the FAB diagnosis criteria of chronic myelomonocytic leukemia (CMML), i.e., myelodysplastic features, monocytosis over…”
Get full text